Resealed Erythrocytes as Drug Carrier Systems
Keywords:
Resealed erythrocytes, Drug carriers, Drug loading, Drug EfficiencyAbstract
Among the various carriers used for targeting drugs to various body tissues, the cellular carriers meet several criteria desirable in clinical applications, among the most important being biocompatibility of carrier and its degradation products. Leucocytes, platelets,erythrocytes, nanoerythrocytes, hepatocytes, and fibroblasts etc. have been proposed as cellular carrier systems. Among these, the erythrocytes have been the most investigated and have found to possess greater potential in drug delivery. Biopharmaceuticals, therapeutically significant peptides and proteins, nucleic acid-based biological, antigens, anticancer drug and vaccines, are among the recently focused pharmaceuticals for being delivered using carrier erythrocytes. Erythrocytes, also known as red blood cells, and have been extensively studied for their potential carrier capabilities for the delivery of drugs. The biocompatibility, nonpathogenicity, non-immunogenicity and biodegradability make them unique and useful carriers. Carrier erythrocytes are prepared by collecting blood sample from the organism of interest and separating erythrocytes from plasma. By using various methods the cells are broken and the drug is entrapped into the erythrocytes, finally they are resealed and the resultant carriers are then called "resealed erythrocytes". So many drugs like aspirin, steroid, cancer drug which having many side effects are reduce by resealed erythrocyte. Current review highlights isolation, drug loading methods, Evaluation methods and applications of resealed erythrocytes for drug delivery.
Downloads
References
R. Green and K.J.Widder, Methods in Enzymology (Academic Press, San Diego, 1987), p. 149.
C. Ropars, M. Chassaigne, and C.Nicoulau, Advances in the BioSciences, (Pergamon Press, Oxford, 1987), p. 67.
D.A. Lewis and H.O. Alpar, “Therapeutic Possibilities of Drugs Encapsulated in Erythrocytes,” Int. J. Pharm. 22, 137–146 (1984).
U. Zimmermann, Cellular Drug-Carrier Systems and Their Possible Targeting In Targeted Drugs, EP Goldberg, Ed. (John Wiley & Sons, New York, 1983), pp. 153–200.
S. Jain and N.K. Jain, “Engineered Erythrocytes as a Drug Delivery System,” Indian J. Pharm. Sci. 59, 275–281 (1997).
M.J. Telen, “The Mature Erythrocytes,” in Winthrob’s Clinical Hematology, R. Lee et al., Eds. (Lea &Febiger, Philadelphia, PA, 9th ed., 1993), pp. 101–133.
A.C.Guyton and J.E.Hall,“Red Blood Cells,Anemia and Polycytemia,” in Textbook of Medical Physiology (W.B. Saunders, Philadelphia, PA, 1996), pp. 425–433.
G.J. Torotra and S.R. Grabowski, “The Cardiovascular System: TheBlood,” in Principles of Anatomy and Physiology (Harper Collins CollegePublishers, New York, NY, 7th ed., 1993), pp. 566–590.
G. Gardos,“Akkumulation de KaliumOnenDurchMenschicheBlutkorperchen,” Acta Physiol. Acad. Sci. Hung 6, 191–196 (1953).
G.M. Iher, R.M. Glew, and F.W. Schnure, “Enzyme Loading of Erythrocytes,” Proc. Natl. Acad. Sci. USA 70, 2663–2666 (1973).
U. Zimmermann, Jahresbericht der KernforschungsanlageJulich GmbH (Nuclear Research Center, Julich, 1973), pp. 55–58.
V. Jaitely et al., “Resealed Erythrocytes: Drug Carrier Potentials and Biomedical Applications,” Indian Drugs 33, 589–594 (1996).
S.J. Updike and R.T.Wakamiya, “Infusion of Red Blood Cell-Loaded Asparaginase in Monkey,” J. Lab. Clin.Med. 101, 679–691 (1983).
H.O. Alpar and W.J. Irwin, “Some Unique Applications of Erythrocytes as Carrier Systems,” Adv. Biosci. (series) 67, 1–9 (1987).
H.C. Eichler et al., “In Vitro Drug Release From Human Carrier Erythrocytes,” Adv. Biosci. (series) 67, 11–15 (1987).
N. Talwar and N.K. Jain,“Erythrocytes as Carriers of Primaquin Preparation: Characterization and Evaluation,” J. Controlled Release 20,133–142 (1992).
H.O.Alpar and D.A. Lewis, “Therapeutic Efficacy of Asparaginase Encapsulated in Intact Erythrocytes,” Biochem. Pharmacol. 34, 257–261 (1985).
K.Adriaenssens et al.,“Use of Enzyme-Loaded Erythrocytes in In Vitro Correction of Arginase Deficient Erythrocytes in Familiar Hyperargininemia,” Clin. Chem. 22, 323–326 (1976).
U. Sprandel, “Towards Cellular Drug Targeting and Controlled Release of Drugs by Magnetic Fields,” Adv. Biosci. 67, 243–250 (1987).
H.G. Eichler et al., “In Vivo Clearance of Antibody-Sensitized Human Drug Carrier Erythrocytes,” Clin. Pharmacol. Ther. 40, 300–303 (1986).
Published
How to Cite
Issue
Section
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright © Author(s) retain the copyright of this article.
